Chapter 16 – Comprehensive Immunomonitoring to Guide the Development of Immunotherapeutic Products for Cancer

摘要: Immunotherapy exploits the effector mechanisms of immune system to combat cancer. A number immunotherapeutic compounds are now firmly anchored in current treatment cancer patients. For newly developed therapeutic entities, study patient’s response remains an essential component clinical trials. Under ideal circumstances, this analysis is accomplished by various laboratory assays that measure differences wanted and unwanted parameters before, during, after treatment, at both systemic local levels, with ultimate aim identifying correlates biological activity as well outcome. The biomarker identification process assisted a harmonization data reporting, because enables comparison datasets obtained testing similar products different trials. Moreover, systematic use better understand strengths, weaknesses efficacy modalities can guide decision making regard further development, possibly encouraging investigators move forward into larger trials or optimize approach. This chapter provides overview immunomonitoring principles promote development effective immunotherapeutics for treatment.